The Congressional Budget Office released its long-term budget outlook. This report should have sparked a national discussion about societal aging, but big media largely ignored it.
Fortunately, there are signs that smart investors are hedging this failure by investing in regenerative medicine (RM).
Over the last few years, the CBO has emerged as one of the few grownups in the room. Its annual budget projections have focused on population aging as the main driver of US federal deficit and the debt.
The core message of "The 2017 Long-Term Budget Outlook" is simple: Mandated transfer payments for our increasingly older demographic are just too much.
These costs have crippled the federal government and the private sector. The CBO warns that this is causing economic instability. As a result, a cascade of financial crises is more and more likely.
Only three parts of the budget are growing in relation to the whole. They are Social Security, health care, and net interest.
Social Security is clearly about the aged, so are increased healthcare costs. The CBO says those costs will continue to rise.
The reason? We are living longer and new treatments for age-related diseases continue to emerge. But even if dramatic cuts are made to benefits for the aged, it will only slow the meltdown.
Why? Long-term demographic trends will continue. Life expectancies will keep rising as birthrates fall.
Progressive Approval Could Be a Game Changer for RM
Japan is ahead of the curve in terms of demographics, but the US will soon get there. It is important to note that Japan has failed to produce political solutions to its budgetary woes.
But Japan has started to look at this problem through a different lens. These economic issues can be solved by addressing aging itself.
Japanese lawmakers have instituted progressive approval for regenerative medicine (RM). That means after successful safety trials, RM therapies can be approved. Data will then be collected and made public.
Critics of progressive approval claim it could legalize ineffective treatments. The Japanese think that the risk of delaying true anti-aging therapies is greater than the risk of approving ineffective treatments.
Japanese leadership seems to have had a major impact on the investment community. Now, US firms are eyeing the prospect of gaining much faster approvals in Japan.
This has major financial implications for RM biotechs.
Investing in Regenerative Medicine
A recent report from Goldman Sachs includes a section titled “The Coming Age of Regenerative Medicine.”
A Business Insider article about the report is aptly titled “Money is pouring in to a hot new area of science that could change the way we think about aging.
According to the article, “venture capital in companies pursuing regenerative medicine increased from $296 million in 2011 to $807 million in 2016, growing roughly 34% year-over-year.”
The author also writes that, “by the report's count, 80 regenerative-medicine companies received funding in the last three years, and the deals related to regenerative medicine accounted for almost half of the top venture-capital deals in 2015 and 2016.”
Two years ago, Fed Chair Janet Yellen threw cold water on biotech. She compared it to overheated social media.
I think Yellen was wrong. And her off-the-cuff comment hurt startups struggling to find funds in order to survive.
On the other hand, economist John Mauldin has long predicted that there will be a bubble following the public’s realization of the power of emerging RM.
But bubbles aren’t uniform things. History teaches us that under- and overvalued companies exist at almost all times.
Some of the companies covered in the Goldman report seem overvalued to me. Analysts, though, are frequently wrong.
We never know what a company is truly worth until its products are judged by consumers.
The Goldman report discusses Samumed, a private RM company. With $300 million in funding, it’s valued at a staggering $12 billion. Samumed’s drug platform aims to regenerate various tissues such as bone, cartilage, hair, and skin.
As Samumed is not yet public, my interest in the company is academic. The larger question is what it means to more established RM companies.
AgeX Plans to Reverse Aging
The original RM company, Geron, is now folded into BioTime subsidiary Asterias. BioTime (*see disclosure below) is the core of my RM portfolio. This is largely because of Michael West, who pioneered the SCI therapy at Geron over 20 years ago.
To date, West's stem cell treatment for spinal cord injury is the most successful example of RM, but it’s 20 years old. Since that time, West’s research has progressed much further.
Last week, BioTime announced a new subsidiary, AgeX. AgeX has a range of stem cell IPs aimed at conditions such as cardiovascular repair and diabetes.
The true goals of AgeX, though, are much more radical. West intends to reverse aging … hence the company name.
He believes he can reactivate embryonic gene pathways to completely regenerate limbs and organs, including eyes, joints, and hearts. AgeX’s induced tissue regeneration technology would not only regenerate damaged and missing tissues.
It would turn back the biological clock of aging. West gave an excellent talk on this new science in his keynote address at the 2016 World Stem Cell Summit.
If he’s right, we’ll still have lots of problems, but the cost of age-related diseases won’t be one of them.